The science driving biomedical research in the 21st Century has become increasingly complex. The information available from the fields of genomics, molecular biology pharmacology medicinal chemistry and other drug discovery technologies has reached overwhelming proportions.

Private investors, as well as experts in biotechnology and pharmaceutical company arenas, have limited time to assess the scientific and commercial value of a virtually unlimited number of new opportunities.

The ability to prioritise such opportunities and select those that are novel and which can be used to discover new drug targets and drug treatments is a complex and challenging process.

Only a small proportion of research projects are worth pursuing and an even smaller proportion are ultimately successful. There are few individuals in the world with the scientific and commercial experience who can offer cutting-edge knowledge of the relevant therapeutic area.

There is therefore a clear need for a resource which can provide independent, unbiased assessment of individual projects for the venture capital community and pharmaceutical companies.